The risk of Coronavirus disease 2019 (COVID-19) in patients with bullous pemphigoid and pemphigus: A population-based cohort study

Published: 02-03-2021| Version 1 | DOI: 10.17632/f3rcw5rfjz.1
Contributors:
Khalaf Kridin,
Yochai Schonmann ,
Orly Weinstein,
Enno Schmidt,
Ralf Ludwig,
Arnon D Cohen

Description

How does this article integrate into what was already known Patients with BP and pemphigus do not have an increased risk of COVID-19 infection relative to control individuals. Patients with BP may have an elevated COVID-19-associated mortality. How does it change practice? That is, what does the article mean to the practice of dermatology, and what should you do as a result of having read this article? What should change in the way you practice COVID-19-positive BP patients should be followed and monitored closely. Given that the intake of systemic corticosteroids and immunosuppressive adjuvants did not predict worse COVID-19 outcomes, these drugs should not be ceased during the pandemic.

Files